Inconsistent dosing, contamination, residual solvents, and improper storage conditions can significantly increase risk. These studies have generally demonstrated low toxicity, strong tolerance, and minimal adverse effects across a range of doses. Most of the available data on BPC-157 comes from animal and preclinical studies. By definition, Grade A evidence is evidence about which the Panel has a high level of certainty, Grade B evidence is evidence about which the Panel has a moderate level of certainty, and Grade C evidence is evidence about which the Panel has a low level of certainty. The categorization of evidence strength is conceptually distinct from the quality of individual studies. Evidence tables (for included studies) and evidence profiles (showing estimates of effect for the outcomes of interest) were generated and presented to the Panel. Minimal data were found regarding outcomes of frailty, risk of venous thromboembolism, hyperestrogenemia, sleep apnea, prostate biopsy, recurrence of treated prostate cancer, and incidence of breast cancer. Of the outcomes included in the protocol of this systematic review, data were available on quality of life (QoL), sexual function, cardiovascular events, anemia, bone health, insulin resistance, cardiovascular risk factors, mood, cognitive function, body composition, and numerous adverse events. Testosterone therapy refers to all forms of treatment that are aimed at increasing serum testosterone, including exogenous testosterone as well as alternative strategies, such as selective estrogen receptor modulators (SERMs), human chorionic gonadotropin (hCG) or aromatase inhibitors (AIs). The Panel explicitly uses the term testosterone therapy rather than testosterone replacement therapy or testosterone supplementation to be in keeping with the beliefs of the current thought leaders in the field. A systematic review of the published literature was conducted to answer these key questions and provide the evidence base for the guideline. Hypogonadism has more recently been used interchangeably with the idea of low testosterone production alone. Commercially manufactured testosterone products should be prescribed rather than compounded testosterone, when possible. Clinicians should not prescribe alkylated oral testosterone. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions. In second pass, an additional 419 studies were excluded. Men who have had exposure of their testes during radiation therapy, either through direct or scatter radiation, are possibly at risk for low testosterone and the Panel recommends total testosterone measurement in such patients. It is believed that as many as one-third of older men have unexplained anemia,77 and data from observational studies indicate that there is a significant association between low testosterone levels and reduced hemoglobin (Hb) levels. Despite the methodological limitations, individual studies have shown a link between low testosterone levels and ED. Among men with traditional (10p.m. to 6a.m.) sleep patterns, peak testosterone values occur around 3-8a.m., with 32-39% of the diurnal total decline occurring within the first 30 minutes of waking.18-23 Older men experience diurnal blunting and more stability in testosterone levels throughout the day, while younger men undergo greater variation. Given the growing concern and need for proper testosterone therapy, the AUA identified a need to produce an evidence-based document that informs clinicians on the proper evaluation and management of testosterone deficient patients. The explosion in the use of testosterone in the past decade is multifactorial in its etiology, including the increased use of direct-to-consumer advertising, which has resulted in greater patient knowledge and demand; relaxation of the indications for testosterone prescribing by clinicians; and the establishment of clinical care centers devoted to men's health, testosterone treatment, and anti-aging strategies. Clinicians should discuss the risk of transference with patients using testosterone gels/creams. All men with testosterone deficiency should be counseled regarding lifestyle modifications as a treatment strategy. Patients should be informed that the evidence is inconclusive whether testosterone therapy improves cognitive function, measures of diabetes, energy, fatigue, lipid profiles, and quality of life measures. Patients should be informed that testosterone therapy may result in improvements in erectile function, low sex drive, anemia, bone mineral density, lean body mass, and/or depressive symptoms. Clinicians should inform testosterone deficient patients that low testosterone is a risk factor for cardiovascular disease. PSA should be measured in men over 40 years of age prior to commencement of testosterone therapy to exclude a prostate cancer diagnosis. Clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate cancer. Prior to offering testosterone therapy, clinicians should measure hemoglobin and hematocrit and inform patients regarding the increased risk of polycythemia. Given the clinical and commercial testosterone landscape, the American Urological Association (AUA) identified a need to produce an evidence-based document that informs clinicians on the proper assessment and management of patients with testosterone deficiency. The aim of the study was to develop and validate a practical assay of clinically relevant testosterone levels in human plasma and saliva. In the case of topical patches, the testosterone levels achieved directly relate to the amount of surface area exposed to drug.430 Topical gels and liquids generally demonstrate less variability in absorption uptake when compared to other therapies.417 After application, steady state levels are achieved within hours, with testosterone levels returning to baseline within 4 days of discontinuation.418, 419 Meta-analyses of RCTs and cohort studies provide the highest levels of evidence and reliability, followed by individual RCTs, prospective cohorts, retrospective cohorts, and observational studies. There are several areas in the testosterone deficiency space, more specifically, epidemiology, diagnosis, treatment and adverse events, which warrant more detailed investigation. Exogenous testosterone therapy has been shown to interrupt normal spermatogenesis and can put patients in severely oligospermic or azoospermic states and should not be used in men trying to conceive. At the end of the study, total testosterone increased in both groups with neither group deriving more benefit than the other (p ≥ 0.244). At baseline, 22 patients had total testosterone 375 While seven of the trials in the above analysis showed decreased, but statistically insignificant, odds of having a cardiac event while on testosterone therapy, one trial did show an increased risk. A meta-analysis of RCTs developed in support of this guideline indicate that there is no significant difference in MACE in men on testosterone therapy when compared to placebo. A total of 651 men (mean age 62.9 years) received oral, transdermal, or IM testosterone, while 433 men received placebo for a period of 12 weeks to 36 months.
